Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Terminated Initiated Jan 24, 2020 (7 years ago)

Pioglitazone and Metformin Hydrochloride Tablets

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Subpotent Drug: Out of specification assay result, below specification, for two lots of Pioglitazone And Metformin Hydrochloride Tablets.

Cause type: Wrong potency / content

Sub- or super-potent product, or a failed content-uniformity / assay test. You may receive too little or too much active ingredient - a direct dosing risk. All wrong potency / content recalls.

What was recalled

Pioglitazone and Metformin Hydrochloride Tablets, USP 15 mg/500 mg, Rx Only, 60-count bottle, Manufactured for Macleods Pharma USA, Inc. Plainsboro, NJ 08536, Manufactured by: Macleods Pharmaceuticals Ltd. Baddi, Himachal Pradesh, India, NDA 33342-176-09

Affected NDC 33342-0176-09

Compare with the code on your package — it is the most precise check available.

Drug: Metformin Category: Diabetes Medication

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Pioglitazone and metformin hydrochloride
NDC 33342-0176
METFORMIN HYDROCHLORIDE 500 mg/1; PIOGLITAZONE HYDROCHLORIDE 15 mg/1 Tablet
Oral
Macleods Pharmaceuticals Limited Rx
Recalling firm
Macleods Pharma Usa Inc
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0838-2020 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Metformin recalls

See all
Class II · Moderate risk

Synjardy XR Tablets

CGMP Deviations: An incorrect detergent was used and the required swab sampling was not performed on a production hopper that had previously been used for a different product.

Ongoing cGMP deviation Boehringer Ingelheim Pharmaceuticals, Inc. D-0657-2026

Other recalls by Macleods Pharma Usa Inc

All 2020 recalls
Class III · Low risk

Levofloxacin Tablets

Mismatching of the embossing on the tablets (T7) with the embossing mentioned in the package insert (ML63) in the distributed bottles.

Terminated Labeling / mix-up Macleods Pharma USA, INC NDC 33342-022-08 D-0162-2023
Class II · Moderate risk

Eszopiclone Tablets

Shortfill: customer complaints of one to three tablets were reported missing from 30 count bottles.

Terminated Failed specification Macleods Pharma Usa Inc NDC 33342-299-07 D-1174-2022